The telmisartan market comprises drugs used for the treatment of hypertension or high blood pressure. Telmisartan helps control blood pressure by relaxing blood vessels and reducing strain on the heart. It is prescribed to patients with essential hypertension who cannot achieve goal blood pressure with other antihypertensive drugs alone. It is available as an oral formulation and helps lower the risk of stroke, heart attack, and other serious health issues arising from uncontrolled high blood pressure.

The global telmisartan market is estimated to be valued at US$ 4,109.53 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics: One of the key drivers for the growth of the telmisartan market is the rising prevalence of hypertension across the globe. According to the World Health Organization (WHO), hypertension currently affects over 1.13 billion people worldwide. It accounts for more deaths globally than any other risk factor and its prevalence is predicted to increase to 1.56 billion people by 2025. The increasing cases of hypertension are expected to boost demand for effective drugs for its treatment like telmisartan. Furthermore, the patent expiry of several other antihypertensive drugs is also projected to positively impact the telmisartan market growth over the forecast period. The availability of low-cost generic versions of telmisartan following patent expirations will make the drug accessible to more patients globally, thereby fueling market revenue.

SWOT Analysis

Strength: Telmisartan is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure. It has demonstrated efficacy in clinical studies with a good safety profile. Being an off-patent drug, telmisartan is offered at affordable prices by many generic drug manufacturers. This provides patients better accessibility and adherence to treatment.

Weakness: The telmisartan market faces intense competition from alternative angiotensin receptor blockers that are also widely available as low-cost generics. Additionally, pharmaceutical companies face pricing pressures that constrain their ability to invest significantly in research and development of new formulations or indications.

Opportunity: The prevalence of hypertension and cardiovascular diseases is steadily increasing worldwide driven by aging populations and lifestyle changes. This raises the potential for growth in demand for affordable antihypertensive drugs like telmisartan. Further opportunities exist in developing countries and emerging markets where treatment rates need to improve.

Threats: Patent expirations of blockbuster drugs force companies to focus on niche segments or shift to biosimilars, impacting investments in conventional generics. Stringent regulatory pathways also delay approval of new generic formulations. Additionally, alternative treatment options or newly developed antihypertensive drug classes can potentially capture market share.


Key Takeaways

The Global Telmisartan Market Demand is expected to witness steady growth over the forecast period driven by increasing treatment needs for cardiovascular diseases. The global telmisartan market is estimated to be valued at US$ 4,109.53 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031.

Regional analysis indicates Asia Pacific as the fastest growing regional market accounting for over 30% of global demand in 2024. The growing healthcare expenditures in China, India and other developing nations are supporting improved diagnosis and management of conditions like hypertension. North America currently dominates the global telmisartan market with the United States representing the largest share. Key factors influencing high consumption in the region include well-established healthcare systems, awareness about treatment and greater affordability of medicines. While demand is projected to rise moderately in the forecast period, pricing pressures and availability of alternative treatment options could impact overall growth rates in North America.

Key players operating in the telmisartan market are Global Self Storage Inc., U-Haul International Inc. (Amerco), Urban Self Storage Inc., Life Storage Inc., Amsdell Cos./Compass Self Storage, CubeSmart LP, All Storage, National Storage Affiliates Trust, National Storage REIT, Safestore Holdings PLC, (Great Value Storage) World Class Capital Group LLC, Simply Self Storage Management LLC, SmartStop Asset Management LLC, StorageMart, Metro Storage LLC, Prime Storage Group, and W. P. Carey Inc. These companies focus on developing generic formulations, new fixed-dose combinations and exploring business expansion opportunities in emerging markets.

For more details on the report, Read-https://www.insightprobing.com/telmisartan-market-trends-size-and-share-analysis/